BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptoms ubarilan SARSCoV2 COVID19 Vaccine Vaccination LongCOVID BNT162b2
By Pooja Toshniwal PahariaSep 12 2022Reviewed by Aimee Molineux In a recent study published in npj Vaccines, researchers assessed the association between Pfizer-BioNTech’s severe acute respiratory syndrome coronavirus-2 BNT162b2 messenger ribonucleic acid vaccination and the incidence of post-coronavirus disease 2019 symptoms among Israeli adults.
About the study In the present study, researchers determined whether BNT162b2 vaccination was associated with the incidence of long COVID symptoms. The prime study outcome was the fraction of study participants who reported particular health outcomes based on the status of SARS-CoV-2 infection and vaccination status. The questionnaires were available in four languages: Arabic, Hebrew, English, and Russian, and binomial regression modeling was used to compare vaccinated individuals with unvaccinated and uninfected individuals, concerning long COVID symptoms.
Out of 951 SARS-CoV-2-infected individuals, 67% had received COVID-19 vaccinations, 340 individuals had received single vaccination, and 294 individuals had received ≥2 vaccine doses vaccinations). Out of 2,447 SARS-CoV-2-naive adults without prior COVID-19 history, 0.9% , 49% , and 30% had received single, double and triple doses, respectively, and the remaining 20% were unvaccinated.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction - Journal of NeuroinflammationCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. Although COVID-19 was initially described as a respiratory disease, there is growing evidence that SARS-CoV-2 is able to invade the brains of COVID-19 patients and cause cognitive impairment. It has been reported that SARS-CoV-2 may have invasive effects on a variety of cranial nerves, including the olfactory, trigeminal, optic, and vagus nerves, and may spread to other brain regions via infected nerve endings, retrograde transport, and transsynaptic transmission. In addition, the blood–brain barrier (BBB), composed of neurovascular units (NVUs) lining the brain microvasculature, acts as a physical barrier between nerve cells and circulating cells of the immune system and is able to regulate the transfer of substances between the blood and brain parenchyma. Therefore, the BBB may be an important structure for the direct and indirect interaction of SARS-CoV-2 with the brain via the blood circulation. In this review, we assessed the potential involvement of neuroinvasion under the SARS-CoV-2 infection, and the potential impact of BBB disorder under SARS-CoV-2 infection on cognitive impairment.
Consulte Mais informação »
Small molecule inhibitor found to be effective against SARS-CoV-2 variantsIn a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).
Consulte Mais informação »
Discovery of antibodies that may eliminate the need for COVID vaccinesIn a recent study published in the journal Communications Biology , researchers evaluated the efficacy of monoclonal antibodies (mAbs) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
Consulte Mais informação »
SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical useIn a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).
Consulte Mais informação »